News
LMDX
--
0.00%
--
LumiraDx rapid COVID-19 test gets WHO emergency use listing
LumiraDx (NASDAQ:LMDX) said it received the World Health Organization's (WHO) Emergency Use Listing (EUL) for its rapid COVID-19 antigen assay LumiraDx SARS-CoV-2 Ag Test. The London-based company said that in in studies
Seekingalpha · 1d ago
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organizat...
Benzinga · 1d ago
BRIEF-Lumiradx Receives WHO Emergency Use Listing For Sars-Cov-2 AG Test
reuters.com · 1d ago
LumiraDx Secures WHO's Emergency Use Listing for COVID-19 Antigen Test
MT Newswires · 1d ago
BRIEF-LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
reuters.com · 2d ago
LumiraDx Says Ultra COVID-19 Test Gets CE Marking
MT Newswires · 2d ago
Raymond James Sees 'Pipeline Key Success Factor' For This MedTech Stock
Benzinga · 05/12 19:43
--Raymond James Adjusts LumiraDx's Price Target to $7 from $9, Keeps Outperform Rating
MT Newswires · 05/12 12:18
--Ladenburg Thalmann Adjusts LumiraDx's Price Target to $14 from $15.25, Keeps Buy Rating
MT Newswires · 05/12 12:16
--Raymond James Lowers LumiraDx's Price Target to $7 From $9, Maintains Outperform Rating
MT Newswires · 05/12 12:00
BRIEF-LumiraDx Reports First Quarter 2022 Results
reuters.com · 05/11 20:04
LumiraDx Reports First Quarter 2022 Results
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the first quarter ended March 31, 2022.
PR Newswire · 05/11 20:01
LumiraDx Q1 Net Loss Widens, Missing Wall Street Expectations; Revenue Jumps Over 18% to Exceed Analyst Estimates
MT Newswires · 05/11 16:25
-- Earnings Flash (LMDX) LUMIRADX Posts Q1 Revenue $126.4M, vs. Street Est of $113.4M
MT Newswires · 05/11 16:10
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022. On the day of the release, LumiraDx will host a conference call and webcas...
PR Newswire · 04/29 12:02
50 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.
Benzinga · 03/29 09:11
LumiraDx at a post-IPO low on expiry of lockup period - Evercore ISI
The shares of the diagnostic company LumiraDx (LMDX -22.7%) have recorded the biggest intraday loss Monday on above-average volume in a move Evercore ISI analyst Vijay Kumar attributed to the
Seekingalpha · 03/28 19:36
AMC, VIEW and COE among mid-day movers
Gainers: DatChat (DATS) +82%. Hycroft Mining Holding Corporation (HYMC) +66%. Plantronics (POLY) +50%. Kaixin Auto (KXIN) +31%. AMC Entertainment Holdings (AMC) +25%. TC Biopharm (TCBP) +23%. Creative Medical Technology (CELZ) +21%. Immunome (IMNM) +21%. C...
Seekingalpha · 03/28 16:57
35 Stocks Moving In Monday's Mid-Day Session
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96  following reports regarding potential future investments from AMC CEO, Adam Aron.
Benzinga · 03/28 16:11
--Raymond James Lowers Price Target for LumiraDx to $9 From $13, Maintains Outperform Rating
MT Newswires · 03/11 10:57
Webull provides a variety of real-time LMDX stock news. You can receive the latest news about Lumiradx Limited through multiple platforms. This information may help you make smarter investment decisions.
About LMDX
LumiraDx Limited is a diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The Company has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. It has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.